Skip to main content
ConductScienceScienceDex
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

521

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

521 results for “Patient survival”

Learn how ShareScore rates datasets ↗
geo16/100

Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel genes associated with progression and survival in human patients

GEO Series GSE181207. Mus musculus. 23 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenAug 2021View details →
geo16/100

Loss of SOX2 expression induces cell migration via Vimentin up-regulation and serves as unfavourable risk factor for poor survival of head and neck squamous cell carcinoma patients

GEO Series GSE61599. Homo sapiens. 4 samples. Type: Expression profiling by array.

openGEO-OpenSep 2014View details →
geo16/100

Elevated ETV6 expression in glioma promotes an aggressive in vitro phenotype associated with shorter patient survival

GEO Series GSE155052. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenJan 2021View details →
geo16/100

Glioblastoma Molecular Characteristics and Immune Microenvironment Associated with Survival Outcomes in Patients Treated with Dendritic Cell Vaccination

GEO Series GSE249282. Homo sapiens. 58 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenDec 2023View details →
geo16/100

Epigenetic mechanism and survival prognosis analysis of serum exosomes from ovarian cancer patients based on sequencing technology and Bioinformatics

GEO Series GSE194238. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenJun 2022View details →
geo16/100

Molecular Characterization of the Vasculature of Patients with Infiltrating Ductal Carcinoma generates a Gene Signature predictive of Breast Cancer Survival

GEO Series GSE43379. Homo sapiens. 40 samples. Type: Expression profiling by array.

openGEO-OpenApr 2013View details →
geo16/100

NF-kB activation confers a prolonged event-free-survival in newly diagnosed myeloma patients harboring t(4;14) treated with bortezomib.

GEO Series GSE31272. Homo sapiens. 34 samples. Type: Genome variation profiling by SNP array; SNP genotyping by SNP array.

openGEO-OpenSep 2015View details →
geo16/100

WNT11/ROR2 signaling is associated with tumor invasion and poor survival in breast cancer [patients]

GEO Series GSE161865. Homo sapiens. 31 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenFeb 2022View details →
geo16/100

miRNA profiling of small intestinal neuroendocrine tumors defines novel molecular subtypes and identifies miR-375 as a biomarker of patient survival

GEO Series GSE103317. Homo sapiens. 54 samples. Type: Non-coding RNA profiling by array.

openGEO-OpenAug 2018View details →
geo16/100

A Methylation-Based Signature Predicts Survival In Hepatocellular Carcinoma Patient

GEO Series GSE56588. Homo sapiens. 243 samples. Type: Methylation profiling by genome tiling array.

openGEO-OpenFeb 2015View details →
geo16/100

Whole transcriptome expression profiling of pancreatic cancers patients with T4 stage but diametrically opposing survival outcomes

GEO Series GSE201358. Homo sapiens. 20 samples. Type: Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing.

openGEO-OpenApr 2022View details →
geo16/100

A β-catenin-regulated RNA processing transcriptional program imposes chemotherapy resistance and predicts T-ALL patient survival associated with high BRCA1 levels [RNA-Seq]

GEO Series GSE196985. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenDec 2022View details →
geo16/100

Genomic profiles and survival prognosticators in African-American patients with acute myeloid leukemia

GEO Series GSE266498. Homo sapiens. 13 samples. Type: Expression profiling by high throughput sequencing; Other.

openGEO-OpenMay 2024View details →
geo16/100

Gene copy number variations associated with patient survival in uveal melanoma

GEO Series GSE37259. Homo sapiens. 58 samples. Type: Genome variation profiling by SNP array; SNP genotyping by SNP array.

openGEO-OpenFeb 2013View details →
zenodo16/100

Dataset related to article "Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis."

<p>PURPOSE:</p> <p>The aim of the present study was to provide predictive factors for survival outcomes of oligometastatic prostate cancer (PC) patients treated with stereotactic body radiation therapy (SBRT) as a metastases-directed therapy (MDT).</p> <p>METHODS:</p> <p>In this cohort study, endpoints included overall survival (OS), progression-free survival (PFS), distant progression-free survival (DFS) and local control of treated metastases (LC). The binary classification tree approach with recursive partitioning analysis (RPA) was applied to stratify the patients into risk groups based on OS, PFS and DPFS; for each endpoint, disease-free interval (DFI) was calculated. We included patients with synchronous or metachronous metastases from prostate adenocarcinoma treated with SBRT.</p> <p>RESULTS:</p> <p>119 Metastases were treated with SBRT in 92 patients. Median follow-up was 22.2&nbsp;months. Rates of OS at 1 and 3&nbsp;years were 96.9% and 88.0%, while DPFS was 51.9% and 20.9%. Recursive partitioning analysis identified three prognostic classes for OS: Class 1: castration-sensitive patients (3&nbsp;years OS 95%); Class 2: castration-resistant patients with low-intermediate risk NCCN disease (3&nbsp;years OS 88.8%); Class 3: castration-resistant patients with high-risk NCCN disease (3&nbsp;years OS 76.9%). Regarding DPFS, RPA divided patients into two classes, according to a cutoff value of DFI of 34&nbsp;months (3&nbsp;years PFS of 28.7% vs 5.8%). Three classes were identified for DPFS: Class 1: DFI&thinsp;&lt;&thinsp;34&nbsp;months (3&nbsp;years DPFS 9.1%); Class 2: DFI&thinsp;&gt;&thinsp;34&nbsp;months and high-risk NCCN PC (3&nbsp;years DPFS 21%); Class 3: DFI&thinsp;&gt;&thinsp;34&nbsp;months and low-intermediate risk NCCN disease (3&nbsp;years DPFS 60.2%).</p> <p>CONCLUSION:</p> <p>Oligometastatic PC represents nowadays a setting of particular interest in which local ablative therapies play a decisive role. In the present study, we recognized the importance of DFI, together with NCCN class risk, to predict the risk of new metastases after SBRT in oligometastatic PC.</p>

restrictedMar 2020View details →
zenodo16/100

Dataset related to article "Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy"

<p>This record contains raw data related to article &ldquo;Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy&quot;</p> <p><strong>Introduction:&nbsp;</strong>Liver and lung are common sites of metastases from colorectal cancer (CRC). Stereotactic body radiation therapy (SBRT) represents a valid treatment, with high rates of local control (LC). In this study, we applied recursive partitioning model-based analysis (RPA) to define class risks for overall survival (OS) and progression free survival (PFS) in oligometastatic CRC patients.</p> <p><strong>Materials and methods:&nbsp;</strong>In this monocentric analysis, we included patients with lung or liver metastases. Patients were candidate to SBRT if a maximum of 5 metastases. End points of the present analysis were LC, PFS, and OS. The binary classification tree approach with RPA was applied to stratify the patients into risk groups based on OS and PFS.</p> <p><strong>Results:&nbsp;</strong>218 patients were treated with SBRT on 371 metastases. Majority of patients (56%) was treated on single lesion, followed by 2 (26.1%) and 3 lesions (14.7%). Median follow-up was 22.7 months. Rates of LC were 84.2% at 1 year and 73.8% at 3 years. Rates of PFS at 1 and 3 years were 42.2% and 14.9%, respectively. RPA identified 3 classes for PFS, according to age and number of metastases with 3-year PFS of 30.6%, 13.5% and 8.4%. Overall survival was 87.2% at 1 year, 51.9% at 3 years, and 36.8% at 5 years. RPA identified 3 nodes. Class 1 included patients with liver metastases (3-year OS 35.2%). Class 2 included patients with lung metastases and DFI &le; 48 months (3-year OS 65%). Class 3 included patients with lung metastases and DFI &gt; 48 months (3-year OS 73.5%).</p> <p><strong>Conclusions:&nbsp;</strong>Stereotactic body radiation therapy can be considered an effective treatment for the management of liver and lung metastases from CRC. With RPA, we identified prognostic risk class to define patients who could benefit the most from SBRT.</p>

restrictedDec 2020View details →
zenodo16/100

DATASET RELATED TO ARTICLE "Resection of primary central nervous system lymphoma: impact of patient selection on overall survival"

<p>Patient characteristics, comorbidities, pre-operatives symptoms, lesion features, post-operatives symptoms, adjuvant therapies, histology, PFS, OS</p> <p>&nbsp;</p>

restrictedJan 2022View details →
zenodo16/100

Dataset related to article "Early age of onset is an independent predictor for worse disease-free survival in sporadic rectal cancer patients. A comparative analysis of 980 consecutive patients "

<p>This record contains raw data related to article &ldquo;Early age of onset is an independent predictor for worse disease-free survival in sporadic rectal cancer patients. A comparative analysis of 980 consecutive patients&quot;</p> <p><strong>Background: </strong> while interest on early-onset colorectal cancer (age &le;49) is on the rise, studies on early-onset rectal cancer (EORC) are limited. The aim of this study was to compare predictors for disease progression/recurrence between sporadic EORC and late-onset RC patients (LORC).</p> <p><strong>Methods: </strong> 163 EORC and 830 LORC operated between January 1st<sup>,</sup> 2010 and April 30th<sup>,</sup> 2021 at a tertiary center were included. Demographics, tumor characteristics, microsatellite status, gene mutations (KRAS, BRAF, NRAS, PI3Kca) and oncologic outcomes were compared. A Cox proportional hazards regression analysis was performed to ascertain the effect of variables on recurrence/progression and death. Recurrence/Progression free survival (R/PFS) and cancer specific survival (CSS) were analyzed by the Kaplan-Meier estimator.</p> <p><strong>Results: </strong> Mean age of EORC was 42.16, (46% aged 45-49). A majority of EORC patients had a family history for CRC (p = 0.01) and underwent total neoadjuvant treatment (p = 0.01). EORC patients showed a higher rate of low-grade tumor differentiation (p &lt; 0.0001), stage III-IV (p = 0.001), microsatellite instability (p = 0.02), locoregional nodal (p = 0.001) and distant metastases (p &lt; 0.0001). Accordingly, more EORC patients underwent adjuvant treatment (p &lt; 0.0001). Mutations were mostly reported among LORC cases (p = 0.04), whereas EORC patients showed a worse R/PFS (p = 0.02), even at stage I (p = 0.04). CSS did not differ (p = 0.11) across groups. Multivariate analysis indicated age of onset (p = 0.04) was an independent predictor for progression/recurrence.</p> <p><strong>Conclusions: </strong> Age of onset was shown to be an independent unfavorable predictor. Delayed diagnosis could explain this effect in the more advanced stages, while the worse outcomes in stage I may suggest a more aggressive disease behavior.</p> <p>&nbsp;</p>

restrictedJan 2022View details →
zenodo16/100

Dataset related to article "Oligoscore: a clinical score to predict overall survival in patients with oligometastatic disease treated with stereotactic body radiotherapy "

<p>This record contains raw data related to article &ldquo;Oligoscore: a clinical score to predict overall survival in patients with oligometastatic disease treated with stereotactic body radiotherapy&quot;</p> <p>Abstract:</p> <p><strong>Background: </strong> to find clinical features that can predict prognosis in patients with oligometastatic disease treated with stereotactic body radiotherapy (SBRT).</p> <p><strong>Material and methods: </strong> Patients with less than 5 metastases in less than 3 different body sites were included in the analysis. Various clinical and treatment parameters were analyzed to create a Cox proportional hazard model for Overall Survival (OS). Subsequently, significant variables were used to create a score.</p> <p><strong>Results: </strong> 997 patients were analyzed. Median OS was 2.61 years, 1 and 3 years OS was respectively 85% and 43%. Location of the primary tumor, performance status, site of irradiated metastases, presence of extratarget non irradiated lesions and RT dose were significant prognostic factors for OS. These parameters were used to create a score and to distinguish three different classes, with median OS of 5.67 years in low risk, 2.47 years in intermediate risk and 1.82 years in high risk group.</p> <p><strong>Conclusion: </strong> moving from easily accessible clinical parameters, a score was created to help the physician&#39;s decision about the better treatment or combination of treatments for the individual patient.</p>

restrictedOct 2022View details →
geo16/100

Chromatin structure predicts survival in glioma patients

GEO Series GSE295378. Homo sapiens. 38 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.

openGEO-OpenApr 2025View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.